136 related articles for article (PubMed ID: 34218422)
1. Predictive factors for refractory stage I and II anti-resorptive agent-related osteonecrosis of the jaw.
Shimizu T; Kim M; Dam TT; Kurihara J; Ogawa M; Makiguchi T; Yokoo S
Oral Radiol; 2022 Apr; 38(2):240-251. PubMed ID: 34218422
[TBL] [Abstract][Full Text] [Related]
2. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
[TBL] [Abstract][Full Text] [Related]
3. Anti-VEGFR therapy is one of the healing inhibitors of antiresorptive-related osteonecrosis of the jaw.
Kanno C; Kaneko T; Endo M; Kitabatake T; Sakuma T; Kanaya Y; Watanabe Y; Hasegawa H
J Bone Miner Metab; 2021 May; 39(3):423-429. PubMed ID: 33196901
[TBL] [Abstract][Full Text] [Related]
4. Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents.
Nakai Y; Kanaki T; Yamamoto A; Tanaka R; Yamamoto Y; Nagahara A; Nakayama M; Kakimoto KI; Ishibashi M; Nishimura K
J Bone Miner Metab; 2021 Mar; 39(2):295-301. PubMed ID: 32886176
[TBL] [Abstract][Full Text] [Related]
5. Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) in urological malignancies: a multi-center retrospective study.
Sakai Y; Shindo T; Sato S; Takahashi A; Kunishima Y; Kato R; Itoh N; Okada M; Tachiki H; Taguchi K; Takayanagi A; Hotta H; Horita H; Matsukawa M; Matsuki M; Nishiyama K; Miyazaki A; Hashimoto K; Tanaka T; Masumori N
J Bone Miner Metab; 2021 Jul; 39(4):661-667. PubMed ID: 33704573
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of surgery and hyperbaric oxygen for antiresorptive agent-related osteonecrosis of the jaw: A subgroup analysis by disease stage.
Watanabe T; Asai K; Fukuhara S; Uozumi R; Bessho K
PLoS One; 2021; 16(1):e0244859. PubMed ID: 33395446
[TBL] [Abstract][Full Text] [Related]
7. Bone scan index of the jaw: a new approach for evaluating early-stage anti-resorptive agents-related osteonecrosis.
Watanabe S; Nakajima K; Mizokami A; Yaegashi H; Noguchi N; Kawashiri S; Inokuchi M; Kinuya S
Ann Nucl Med; 2017 Apr; 31(3):201-210. PubMed ID: 27995542
[TBL] [Abstract][Full Text] [Related]
8. Clinical risk factors for severity and prognosis of antiresorptive agent-related osteonecrosis of the jaw: a retrospective observational study.
Nashi M; Hirai T; Iwamoto T; Takenobu T
J Bone Miner Metab; 2022 Nov; 40(6):1014-1020. PubMed ID: 36166107
[TBL] [Abstract][Full Text] [Related]
9. Associations between Systemic Markers of Bone Turnover or Bone Mineral Density and Anti-Resorptive Agent-Related Osteonecrosis of the Jaw in Patients Treated with Anti-Resorptive Agents.
Tohashi K; Nakabayashi M; Kodani I; Kidani K; Ryoke K
Yonago Acta Med; 2016 Mar; 59(1):45-53. PubMed ID: 27046950
[TBL] [Abstract][Full Text] [Related]
10. Quantitative bone scan imaging using BSI and BUV: an approach to evaluate ARONJ early.
Yamamoto Y; Mitsunaga S; Horikawa A; Hino A; Kurihara H
Ann Nucl Med; 2020 Jan; 34(1):74-79. PubMed ID: 31705367
[TBL] [Abstract][Full Text] [Related]
11. Incidence and Risk of Anti-Resorptive Agent-Related Osteonecrosis of the Jaw after Tooth Extraction: A Retrospective Study.
Shimizu R; Sukegawa S; Sukegawa Y; Hasegawa K; Ono S; Nakamura T; Fujimura A; Fujisawa A; Nakano K; Takabatake K; Kawai H; Nagatsuka H; Furuki Y
Healthcare (Basel); 2022 Jul; 10(7):. PubMed ID: 35885858
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Periodontal Space Widening in Patients with Antiresorptive Drug-related Osteonecrosis of the Jaws (ARONJ) on Panoramic Radiographs.
Assaf AT; Amberg V; Smeets R; Wikner J; Hanken H; Semmusch J; Ewald F; Rashad A; Friedrich RE
Anticancer Res; 2018 Sep; 38(9):5305-5314. PubMed ID: 30194182
[TBL] [Abstract][Full Text] [Related]
13. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.
Shibahara T
Tohoku J Exp Med; 2019 Feb; 247(2):75-86. PubMed ID: 30713280
[TBL] [Abstract][Full Text] [Related]
14. [Surgical treatment for anti-resorptive agents-related osteonecrosis of jaw.].
Ota Y
Clin Calcium; 2017; 27(10):1445-1452. PubMed ID: 28947696
[TBL] [Abstract][Full Text] [Related]
15. Single-center analysis of antiresorptive agent-related osteonecrosis of the jaw in lung cancer patients.
Okamura M; Fujita K; Yamamoto Y; Kanai O; Nakatani K; Horimoto K; Hashimoto M; Sawai S; Shimosato M; Yoshida K; Mio T
Asia Pac J Clin Oncol; 2020 Dec; 16(6):380-384. PubMed ID: 32893984
[TBL] [Abstract][Full Text] [Related]
16. Major histocompatibility complex class II polymorphisms are associated with the development of anti-resorptive agent-induced osteonecrosis of the jaw.
Stockmann P; Nkenke E; Englbrecht M; Schlittenbauer T; Wehrhan F; Rauh C; Beckmann MW; Fasching PA; Kreusch T; Mackensen A; Wullich B; Schett G; Spriewald BM
J Craniomaxillofac Surg; 2013 Jan; 41(1):71-5. PubMed ID: 23218978
[TBL] [Abstract][Full Text] [Related]
17. Quantitative evaluation of anti-resorptive agent-related osteonecrosis of the jaw using bone single photon emission computed tomography in clinical settings: relationship between clinical stage and imaging.
Okui T; Kobayashi Y; Tsujimoto M; Satoh K; Toyama H; Matsuo K
Ann Nucl Med; 2020 Sep; 34(9):620-628. PubMed ID: 32557015
[TBL] [Abstract][Full Text] [Related]
18. Antiresorptive drug-related osteonecrosis of the jaws, literature review and 5 years of experience.
Bernardi S; Di Girolamo M; Necozione S; Continenza MA; Cutilli T
Musculoskelet Surg; 2019 Apr; 103(1):47-53. PubMed ID: 29948937
[TBL] [Abstract][Full Text] [Related]
19. Relationships of opacification in the nasal sinuses, rhinosinusitis, and antiresorptive agent-related osteonecrosis of the jaw.
Matsumoto Y; Yokoi H; Ikeda T; Kawada M; Saito K
Auris Nasus Larynx; 2020 Dec; 47(6):996-1002. PubMed ID: 32591168
[TBL] [Abstract][Full Text] [Related]
20. Antiresorptive agent-related osteonecrosis of the jaw risk in cancer patients before bone-modifying agent therapy: A retrospective study of 511 patients.
Kanno C; Kojima M; Tezuka Y; Yaginuma S; Kanaya Y; Kaneko T
Bone; 2023 Dec; 177():116892. PubMed ID: 37689127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
